Tanaka Hiroki, Hijioka Susumu, Iwaya Hiromichi, Mizuno Nobumasa, Kuwahara Takamichi, Okuno Nozomi, Ito Ayako, Kuraoka Naosuke, Matsumoto Shinpei, Obata Masahiro, Kurita Yusuke, Yasuda Muneji, Shimizu Yasuhiro, Kuroda Hiroaki, Sato Yozo, Haneda Masataka, Sasaki Eiichi, Yatabe Yasushi, Hara Kazuo
Department of Gastroenterology, Aichi Cancer Center Hospital, Japan.
Department of Gastroenterology, Suzuka General Hospital, Japan.
Intern Med. 2018 Dec 15;57(24):3537-3543. doi: 10.2169/internalmedicine.1243-18. Epub 2018 Aug 10.
A 20-year old man was diagnosed with fibrolamellar hepatocellular carcinoma (FLHCC) with multiple lung metastases, and chemotherapy with FOLFOX was administered. Contrast enhanced CT after 3 cycles of FOLFOX showed no disease progression. We therefore performed surgical resection and radiofrequency ablation of the liver lesions and lung metastases, after obtaining the patient's informed consent. The liver lesions and lung metastases tested positive for DNAJB1-PRKACA. The treatment for FLHCC with extrahepatic metastasis has not been established; however, in a few cases, good long-term prognoses were obtained with multidisciplinary therapy. We herein report a case of FLHCC with multiple lung metastases that was treated with multidisciplinary therapies.
一名20岁男性被诊断为伴有多发肺转移的纤维板层型肝细胞癌（FLHCC），并接受了FOLFOX化疗。FOLFOX化疗3个周期后的增强CT显示疾病无进展。因此，在获得患者知情同意后，我们对肝脏病变和肺转移灶进行了手术切除及射频消融。肝脏病变和肺转移灶的DNAJB1-PRKACA检测呈阳性。伴有肝外转移的FLHCC的治疗方法尚未确立；然而，在少数病例中，多学科治疗取得了良好的长期预后。我们在此报告一例采用多学科治疗的伴有多发肺转移的FLHCC病例。
